Budget impact per Cost type
Scenario 1 : With Polatuzumab + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone
Scenario 2: Without Polatuzumab + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone
Budget Impact per Treatment
Scenario 1 : With Polatuzumab + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone
Scenario 2: Without Polatuzumab + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone
Budget With and Without Pola+R-CHP
Scenario 1 : With Polatuzumab + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone
Scenario 2: Without Polatuzumab + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone
Incremental Budget Impact
Treated Patients per year
Total population
Polatuzumab + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone treated population
Subsequent line patients
Scenario 1 : With Polatuzumab + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone
Scenario 2: Without Polatuzumab + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone